JP2023105147A5 - - Google Patents

Download PDF

Info

Publication number
JP2023105147A5
JP2023105147A5 JP2023093802A JP2023093802A JP2023105147A5 JP 2023105147 A5 JP2023105147 A5 JP 2023105147A5 JP 2023093802 A JP2023093802 A JP 2023093802A JP 2023093802 A JP2023093802 A JP 2023093802A JP 2023105147 A5 JP2023105147 A5 JP 2023105147A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ophthalmic pharmaceutical
pharma
composition according
ceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023093802A
Other languages
English (en)
Japanese (ja)
Other versions
JP7839560B2 (ja
JP2023105147A (ja
Filing date
Publication date
Priority claimed from JP2019508247A external-priority patent/JP7297308B2/ja
Application filed filed Critical
Publication of JP2023105147A publication Critical patent/JP2023105147A/ja
Publication of JP2023105147A5 publication Critical patent/JP2023105147A5/ja
Priority to JP2025139461A priority Critical patent/JP2025168426A/ja
Application granted granted Critical
Publication of JP7839560B2 publication Critical patent/JP7839560B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023093802A 2016-08-19 2023-06-07 眼科用医薬組成物及びそれに関する使用 Active JP7839560B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139461A JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377154P 2016-08-19 2016-08-19
US62/377,154 2016-08-19
JP2019508247A JP7297308B2 (ja) 2016-08-19 2017-08-18 眼科用医薬組成物及びそれに関する使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019508247A Division JP7297308B2 (ja) 2016-08-19 2017-08-18 眼科用医薬組成物及びそれに関する使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139461A Division JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Publications (3)

Publication Number Publication Date
JP2023105147A JP2023105147A (ja) 2023-07-28
JP2023105147A5 true JP2023105147A5 (enExample) 2024-04-17
JP7839560B2 JP7839560B2 (ja) 2026-04-02

Family

ID=60935566

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019508247A Active JP7297308B2 (ja) 2016-08-19 2017-08-18 眼科用医薬組成物及びそれに関する使用
JP2023093802A Active JP7839560B2 (ja) 2016-08-19 2023-06-07 眼科用医薬組成物及びそれに関する使用
JP2025139461A Withdrawn JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019508247A Active JP7297308B2 (ja) 2016-08-19 2017-08-18 眼科用医薬組成物及びそれに関する使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139461A Withdrawn JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Country Status (13)

Country Link
US (6) US9867810B1 (enExample)
EP (2) EP4190328A1 (enExample)
JP (3) JP7297308B2 (enExample)
KR (2) KR102472774B1 (enExample)
CN (2) CN116726006A (enExample)
AU (2) AU2017311636B2 (enExample)
CA (1) CA3031370A1 (enExample)
ES (1) ES2934790T3 (enExample)
IL (2) IL264664B2 (enExample)
MX (2) MX2019001877A (enExample)
PL (1) PL3500255T3 (enExample)
PT (1) PT3500255T (enExample)
WO (1) WO2018033792A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
KR102472774B1 (ko) * 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼の状態の治療のためのピロカルピン塩酸塩の使用
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
EP3965732A4 (en) * 2019-05-08 2023-06-14 Harrow IP, LLC PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA AND PROCESS FOR THEIR PREPARATION
BR112022026911A2 (pt) * 2020-09-11 2023-03-28 Intratus Nevada Inc Composições e métodos para tratar presbiopia, hipermetropia, astigmatismo, diminuição da estereopsia e diminuição da sensibilidade ao contraste
MX394625B (es) * 2020-11-12 2025-03-24 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
US20230263727A1 (en) * 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
CN119700989A (zh) 2023-09-28 2025-03-28 苏州普乐康医药科技有限公司 一种α-肾上腺素受体激动剂眼用组合物及其用途
CN117414333A (zh) * 2023-11-30 2024-01-19 南京正科医药股份有限公司 盐酸毛果芸香碱滴眼液及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5698533A (en) 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
TW389694B (en) 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
AU2287597A (en) 1996-03-13 1997-10-01 Laboratoires Merck Sharp & Dohme - Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition
EP0995435B1 (en) 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6605640B2 (en) 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20040058926A1 (en) 2001-05-04 2004-03-25 Rebanta Bandyopadhyay Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20030018382A1 (en) 2001-07-17 2003-01-23 Pflugfelder Stephen C. Process for improving vision
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2839849C (en) 2003-06-13 2017-03-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
ATE439863T1 (de) 2006-12-18 2009-09-15 Jorge Luis Benozzi Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
WO2008074865A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2008094659A2 (en) 2007-01-31 2008-08-07 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
WO2008130591A2 (en) 2007-04-18 2008-10-30 The Gi Company, Inc. Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
CN101754748A (zh) 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20100298335A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011079123A1 (en) 2009-12-23 2011-06-30 Alimera Sciences, Inc. Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
IN2014CN02961A (enExample) 2011-09-20 2015-07-03 Altavista Inst De Invest Medica S A S
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
EP3104851A1 (en) 2014-02-11 2016-12-21 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
KR102472774B1 (ko) * 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도

Similar Documents

Publication Publication Date Title
Chaudhary et al. Contact lenses in dry eye disease and associated ocular surface disorders
JP2019524826A5 (enExample)
EP3031457B1 (en) Medicament comprising pilocarpine and brimonidine
Baikoff et al. Angle-fixated anterior chamber phakic intraocular lens for myopia of-7 to-19 diopters
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
EP2874660B1 (en) Ophthalmic formulation and method for ameliorating presbyopia
Rico-Del-Viejo et al. Nonsurgical procedures for keratoconus management
Hashemian et al. Toric implantable collamer lens for high myopic astigmatism in keratoconic patients after six months
US20220175734A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
Ridley Therapeutic uses of scleral contact lenses
Yang et al. Centration and stability of small-aperture intraocular lens in aberrated eyes
Mannis et al. Contact lens fitting in keratoconus
JP2021534217A5 (enExample)
KR20230042077A (ko) 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법
Doroodgar et al. Visual outcomes of a new implantable Phakic contact lens in patients with stable keratoconus
US20230210821A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
Fedotova et al. Miniscleral lenses in the treatment of patients with dry eye syndrome (first own experience)
Khorrami-Nejad et al. Management of keratoconus with contact lenses
Santos et al. Long-term improvement after the Athens protocol for advanced keratoconus with significant ectasia progression in the fellow eye
Visser Objective and subjective performance of scleral lenses and new advances in scleral lens technologies
Mohaghegh et al. 8-to-10-Year Follow-Up Results of Photorefractive Keratectomy and Risk Factors for Myopia Regression (Including Near Work Activity) in Southeast Iran
Dick et al. Toric phakic intraocular lens
YÜCEKUL Refractive Surgery in Geriatric Population
Natan et al. Clear Lens Extraction with Phacoemulsification Technique in High Myopia Patient: A Case Report
RU2019107585A (ru) Офтальмологические фармацевтические композиции и их применение